Key Points
- Director Raymond Cohen sold 3,330 Kestra Medical Technologies shares at an average price of $29.28, generating $97,502.40. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with 54,790 shares.
- Kestra reported quarterly revenue of $30.97 million but missed earnings expectations, posting a loss of $0.75 per share versus the $0.61 consensus estimate. Analysts expect a full-year loss of approximately $2.45 per share.
- KMTS shares opened at $27.11, near the analysts’ consensus target of $28.38; coverage is mixed, with four Buy, two Hold, and one Sell rating, resulting in an overall consensus rating of Hold.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) Director Raymond Cohen sold 3,330 shares of the business's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total transaction of $97,502.40. Following the transaction, the director owned 54,790 shares in the company, valued at approximately $1,604,251.20. This represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Price Performance
Shares of NASDAQ:KMTS opened at $27.11 on Friday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The business has a fifty day simple moving average of $25.70 and a 200 day simple moving average of $22.99. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -10.15 and a beta of 0.51.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The firm had revenue of $30.97 million during the quarter. As a group, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in KMTS. Eventide Asset Management LLC raised its stake in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock valued at $33,671,000 after acquiring an additional 65,288 shares in the last quarter. Sei Investments Co. boosted its position in Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company's stock worth $4,726,000 after purchasing an additional 43,753 shares during the period. Corient Private Wealth LP boosted its position in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock worth $1,542,000 after purchasing an additional 44,839 shares during the period. Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies during the fourth quarter valued at approximately $9,282,000. Finally, Next Century Growth Investors LLC raised its position in shares of Kestra Medical Technologies by 154.5% in the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company's stock valued at $12,354,000 after purchasing an additional 282,832 shares during the period.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 16th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a "market perform" rating for the company. Finally, Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Kestra Medical Technologies presently has a consensus rating of "Hold" and an average target price of $28.38.
Read Our Latest Analysis on KMTS
About Kestra Medical Technologies
(
Get Free Report)
Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company's primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.
The ASSURE system continuously monitors a patient's heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
